Comments
Strides Pharma Science Limited (Strides) has announced that its step-down, wholly-owned subsidiary, Strides Pharma Global Pte Ltd, Singapore, has received approval for Ethacrynic Acid tablets USP, 25 mg from the US Food & Drug Administration (USFDA).
Ethacrynic acid is in a class of medications called diuretics (‘water pills’). It is used to treat edema (excess fluid held in body tissues) in adults and children caused by medical problems such as cancer, heart, kidney, or liver disease.
The company’s product is a generic version of Edecrin Tablets, 25 mg, of Bausch Health Americas, Inc.
According to IQVIA MAT August 2020 data, the US market for Ethacrynic Acid tablets USP, 25 mg is approximately $14 million. The product will be manufactured at the company’s flagship facility at Bengaluru and will be marketed by Strides Pharma Inc in the US market.
The company has 126 cumulative ANDA filings with the USFDA, of which 92 ANDAs have been approved and 34 are pending approval.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.